A Brief Review of Ongoing Clinical Trials of ADCs in Breast Cancer
Before closing out their discussion on antibody drug conjugate use in breast cancer management, panelists consider ongoing clinical trials in this setting.
EP: 1.Patient Profile 1: A Patient With HER2+ Metastatic BC Treated With T-DXd who Develops ILD
EP: 2.Adverse Event Management With T-DXd in Patients With Breast or Gastric Cancers
EP: 3.Management of Interstitial Lung Disease Related to T-DXd in Breast or Gastric Cancers
EP: 4.Selecting Appropriate Patients with MBC for T-DXd and Counseling for AEs
EP: 5.Sequencing Therapy in MBC in Second Line and Beyond
EP: 6.Patient Profile 2: A Patient With HER2+ MBC Treated With T-DM1 who Develops Neuropathy
EP: 7.Role of T-DM1 in Patients With HER2+ Breast and Gastric Cancers
EP: 8.Managing AEs With Trastuzumab Emtansine in Breast and Gastric Cancers
EP: 9.A Brief Review of Ongoing Clinical Trials of ADCs in Breast Cancer
EP: 10.Patient Profile 3: A Patient with HER2+ Gastric Cancer Treated With T-DXd–who Develops Neutropenia
EP: 11.First- and Second-Line Treatment Options for HER2+ Gastric Cancer
EP: 12.T-DXd in HER2+ Gastric Cancer: Managing Neutropenia and Other AEs
EP: 13.Ongoing Clinical Trials With T-DXd in HER2+ Gastric Cancer
EP: 14.Patient Profile 4: A Patient with HER2+ Gastric Cancer Treated With T-DXd Who Develops Diarrhea
EP: 15.T-DXd in HER2+ Gastric Cancer: Educating Patients About Risk of Diarrhea
EP: 16.Role of the Broader Healthcare Team in Managing AEs Associated With T-DXd
EP: 17.Novel Clinical Trials With ADCs in Gastric Cancer
EP: 18.Practice Pearls for Toxicity Management With ADC Therapy in Breast and Gastric Cancer
Transcript:
Sarah Donahue, MPH, NP, AOCNP: One of the trials in progress with ADCs [antibody-drug conjugates] in breast cancer that could further impact the landscape is the HER2CLIMB trial, which has tucatinib plus trastuzumab deruxtecan. That’s ongoing for patients with metastatic breast cancer with and without brain metastases. Hopefully, the study will show improvement not only in the brain but also elsewhere. It’s super promising.
In addition, there’s a trial with a new antibody-drug conjugate called ARX788, and that will be studied in patients with metastatic breast cancer who have been refractory to TDM-1 [trastuzumab emtansine] or trastuzumab deruxtecan or tucatinib-containing regimens, like the HER2CLIMB regimen. We have a lot of new research happening, and hopefully more treatments for these patients are coming up.
Transcript edited for clarity.
